TCV VACCINES MARKET ANALYSIS

Key Developments

• On October 23, 2024, Zydus Group, a global pharmaceutical company, announced that its Typhoid Vi conjugate vaccine, ZyVac TCV, has received preliminary approval from the World Health Organization (WHO). This approval allows the vaccine to be eligible for purchase by United Nations (UN) procurement agencies, facilitating its distribution in regions most affected by typhoid fever worldwide.
• In May 2023, Malawi initiated a nationwide mass vaccination campaign targeting typhoid fever, measles, rubella, and polio. This effort makes Malawi the third African country to include the typhoid conjugate vaccine (TCV) in its routine immunization program. The campaign aims to reach over 9 million children, nearly half of the nation's population, and features an integrated "catch-up" strategy to provide essential vaccinations along with vitamin A supplements. Supported by Gavi, the Vaccine Alliance, WHO, UNICEF, and other partners, this initiative is crucial for enhancing child health in Malawi.
• In February 2022, the Typhoid Conjugate Vaccine Introduction in Africa Program (THECA) initiated the TyVECO project, a mass vaccination study conducted in Kisantu, Democratic Republic of Congo (DRC). This project aims to collect further data on the effectiveness and feasibility of a mass vaccination campaign using Typbar TCV. TyVECO is a notable milestone as it is the first study assessing the effectiveness of a typhoid conjugate vaccine in Central Africa.